Subscribe to Journal
Get full journal access for 1 year
only $41.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Huff CA, Matsui W. Multiple myeloma cancer stem cells. J Clin Oncol. 2008;26:2895–900.
Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105–11.
Leung-Hagesteijn C, Erdmann N, Cheung G, Keats JJ, Stewart AK, Reece DE, et al. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell. 2013;24:289–304.
Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y, et al. Characterization of clonogenic multiple myeloma cells. Blood. 2004;103:2332–6.
Pilarski LM, Belch AR. Clonotypic myeloma cells able to xenograft myeloma to nonobese diabetic severe combined immunodeficient mice copurify with CD34 (+) hematopoietic progenitors. Clin Cancer Res. 2002;8:3198–204.
Reghunathan R, Bi C, Liu SC, Loong KT, Chung TH, Huang G, et al. Clonogenic multiple myeloma cells have shared stemness signature associated with patient survival. Oncotarget. 2013;4:1230–40.
Carpenter RO, Evbuomwan MO, Pittaluga S, Rose JJ, Raffeld M, Yang S, et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res. 2013;19:2048–60.
Tai YT, Mayes PA, Acharya C, Zhong MY, Cea M, Cagnetta A, et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014;123:3128–38.
de Mel S, Lim SH, Tung ML, Chng WJ. Implications of heterogeneity in multiple myeloma. Biomed Res Int. 2014;2014:232546.
Chang H, Samiee S, Yi QL. Prognostic relevance of CD56 expression in multiple myeloma: a study including 107 cases treated with high-dose melphalan-based chemotherapy and autologous stem cell transplant. Leuk Lymphoma. 2006;47:43–7.
Kerk SA, Finkel KA, Pearson AT, Warner KA, Zhang Z, Nor F, et al. 5T4-targeted therapy ablates cancer stem cells and prevents recurrence of head and neck squamous cell carcinoma. Clin Cancer Res. 2017;23:2516–27.
Tiberghien AC, Levy JN, Masterson LA, Patel NV, Adams LR, Corbett S, et al. Design and synthesis of tesirine, a clinical antibody-drug conjugate pyrrolobenzodiazepine dimer payload. ACS Med Chem Lett. 2016;7:983–7.
Harper J, Lloyd C, Dimasi N, Toader D, Marwood R, Lewis L, et al. Preclinical evaluation of MEDI0641, a pyrrolobenzodiazepine-conjugated antibody-drug conjugate targeting 5T4. Mol Cancer Ther. 2017;16:1576–87.
Sanchez E, Li M, Kitto A, Li J, Wang CS, Kirk DT, et al. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br J Haematol. 2012;158:727–38.
Barlogie B, Mitchell A, van Rhee F, Epstein J, Morgan GJ, Crowley J. Curing myeloma at last: defining criteria and providing the evidence. Blood. 2014;124:3043–51.
We gratefully acknowledge Jeff Carrell (MedImmune) for his assistance with flow cytometry; Terrence O’Day (MedImmune) for statistical support; Deborah Shuman (MedImmune) for editorial assistance during the preparation of this manuscript; and Sepi Farshadi (MedImmune) for help with the preparation of figures. This study was funded by MedImmune, the global biologics R&D arm of AstraZeneca.
KK, EMH, SBT, MF and ND designed experiments, analyzed and interpreted data, and wrote the manuscript; KK, JM, RV, SB, SBT, MF, PGH, RF, BB, CC, LW, RC and Y-TT designed and performed experiments and interpreted data; XX and HZ designed experiments and interpreted data; KCA, RH, PWH and DAT provided guidance, intellectual input, and reviewed the paper; all authors participated in critical review and editing of the manuscript.
Conflict of interest
Y-TT declares that she has no conflict of interest. KCA is the scientific founder of Oncopep and C4 Therapeutics and serves on the advisory boards of MedImmune, Bristol-Myers Squibb, Gilead and Millenium Pharmaceuticals. PWH is an employee of Spirogen and has stock and/or stock interests in AstraZeneca. All other authors are employees of MedImmune or were employees of MedImmune while they were involved with this work and have stock and/or stock interests in AstraZeneca.
Electronic supplementary material
About this article
Cite this article
Kinneer, K., Flynn, M., Thomas, S.B. et al. Preclinical assessment of an antibody–PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells. Leukemia 33, 766–771 (2019). https://doi.org/10.1038/s41375-018-0278-7
Drug Conjugated and Bispecific Antibodies for Multiple Myeloma: Improving Immunotherapies off the Shelf
Military Medical Research (2021)
Therapeutic Advances in Hematology (2021)
Panminerva Medica (2021)
Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects
Current Oncology (2021)